Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 14;118(2):413-5.
doi: 10.1182/blood-2011-01-330704. Epub 2011 May 20.

Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome

Zhuang Zuo  1 , George A Calin, Henrique M de Paula, L Jeffrey Medeiros, Michael H Fernandez, Masayoshi Shimizu, Guillermo Garcia-Manero, Carlos E Bueso-Ramos
Affiliations

Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome

Zhuang Zuo et al. Blood. .

Abstract

Circulating microRNAs (miRNAs) are potential biomarkers for cancer. We examined plasma levels of 2 miRNAs, let-7a and miR-16, in 50 patients with myelodysplastic syndrome (MDS) and 76 healthy persons using quantitative real-time PCR. Circulating levels of both miRNAs were similar among healthy controls but were significantly lower in MDS patients (P = .001 and P < .001, respectively). The distributions of these 2 miRNA levels were bimodal in MDS patients, and these levels were significantly associated with their progression-free survival and overall survival (both P < .001 for let-7a; P < .001 and P = .001 for miR-16). This association persisted even after patients were stratified according to the International Prognostic Scoring System. Multivariate analysis revealed that let-7a level was a strong independent predictor for overall survival in this patient cohort. These findings suggest that let-7a and miR-16 plasma levels can serve as noninvasive prognostic markers in MDS patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Levels of let-7a and miR-16 and survival in patients with MDS and control subjects. Distributions of let-7a and miR-16 plasma levels in 76 healthy control subjects (A-B) and 50 MDS patients (C-D), along with Kaplan-Meier curves showing (E) OS by IPSS risk score (P = .022), (F) PFS by IPSS risk score (P = .063), (G) OS by let-7a level (P < .001), (H) PFS by let-7a level (P < .001), (I) OS by miR-16 level (P = .001), and (J) PFS by miR-16 level (P < .001). INT indicates intermediate.
See this image and copyright information in PMC

References

    1. Cazzola M, Malcovati L. Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536–538. - PubMed
    1. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503–3510. - PubMed
    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088. - PubMed
    1. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008. pp. 88–93.
    1. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113(6):1351–1361. - PMC - PubMed

Publication types